The burden of HIV on society in the developing world
and the price for treatment is enormous. The recent
agreement between the Clinton Foundation and generic
pharmaceutical companies is a major step forward.
Also the cost-effectiveness is superior to treatment of for
example hypercholesterolaemia. However, there are other prices to be paid, since drugs may induce unfavourable and unwanted side effects.
For the future the challenge remains to keep all prices for HIV treatment as low as possible. Only an affordable and harmless HIV treatment might bring the progress of the HIV pandemic to a halt.